Human albumin prevents 6-hydroxydopamine-induced loss of tyrosine hydroxylase in in vitro and in vivo

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Zhang, Li Juan ^a   Xue, Yue Qiang ^b   Yang, Chun ^a   Yang, Wei Hua ^a   Chen, Long ^b   Zhang, Qian Jin ^c   Qu, Ting Yu ^d   Huang, Shile ^b   Zhao, Li Ru ^e   Wang, Xiao Min ^a   Duan, Wei Ming ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c XAVIER UNIVERSITY OF LOUISIANA   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; HUMAN ALBUMIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OXIDOPAMINE; PROTEIN C JUN; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TIRON; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN ASYMMETRY; CELL VIABILITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

ALBUMINS; ANIMALS; CASPASE 3; CELL LINE, TUMOR; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

RATTUS;

EID: 84864023632     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041226     Document Type: Article

References (66)

1. Andersen JK, (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat Med 10.
2. Block ML, Zecca L, Hong JS, (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69.
3. Holtz WA, Turetzky JM, Jong YJ, O'Malley KL, (2006) Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics. J Neurochem 99: 54-69.
4. Lotharius J, Brundin P, (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3: 932-942.
5. Lin E, Cavanaugh JE, Leak RK, Perez RG, Zigmond MJ, (2008) Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J Neurosci Res 86: 108-117.
6. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Munoz-Patino AM, Labandeira-Garcia JL, (2000) Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem 74: 1605-1612.
7. Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S, (2006) 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J Biol Chem 281: 5373-5382.
8. Rodriguez-Pallares J, Parga JA, Munoz A, Rey P, Guerra MJ, et al. (2007) Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J Neurochem 103: 145-156.
9. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, et al. (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15: 991-998.
10. Mielke K, Herdegen T, (2000) JNK and p38 stresskinases - degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol 61: 45-60.
11. Ouyang M, Shen X, (2006) Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J Neurochem 97: 234-244.
12. Bozyczko-Coyne D, Saporito MS, Hudkins RL, (2002) Targeting the JNK pathway for therapeutic benefit in CNS disease. Curr Drug Targets CNS Neurol Disord 1: 31-49.
13. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME, (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331.
14. Emerson TE Jr, (1989) Unique features of albumin: a brief review. Crit Care Med 17: 690-694.
15. Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD, (1997) Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. J Neurosurg 87: 595-601.
16. Belayev L, Alonso OF, Huh PW, Zhao W, Busto R, et al. (1999) Posttreatment with high-dose albumin reduces histopathological damage and improves neurological deficit following fluid percussion brain injury in rats. J Neurotrauma 16: 445-453.
17. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD, (2001) Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 32: 553-560.
18. Belayev L, Pinard E, Nallet H, Seylaz J, Liu Y, et al. (2002) Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke 33: 1077-1084.
19. Gum ET, Swanson RA, Alano C, Liu J, Hong S, et al. (2004) Human serum albumin and its N-terminal tetrapeptide (DAHK) block oxidant-induced neuronal death. Stroke 35: 590-595.
20. Choi WS, Yoon SY, Oh TH, Choi EJ, O'Malley KL, et al. (1999) Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J Neurosci Res 57: 86-94.
21. Han BS, Hong HS, Choi WS, Markelonis GJ, Oh TH, et al. (2003) Caspase-dependent and-independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment. J Neurosci 23: 5069-5078.
22. Moran EC, Kamiguti AS, Cawley JC, Pettitt AR, (2002) Cytoprotective antioxidant activity of serum albumin and autocrine catalase in chronic lymphocytic leukaemia. Br J Haematol 116: 316-328.
23. Bolitho C, Bayl P, Hou JY, Lynch G, Hassel AJ, et al. (2007) The anti-apoptotic activity of albumin for endothelium is mediated by a partially cryptic protein domain and reduced by inhibitors of G-coupled protein and PI-3 kinase, but is independent of radical scavenging or bound lipid. J Vasc Res 44: 313-324.
24. Zoellner H, Hofler M, Beckmann R, Hufnagl P, Vanyek E, et al. (1996) Serum albumin is a specific inhibitor of apoptosis in human endothelial cells. J Cell Sci 109 (Pt 10): 2571-2580.
25. Gallego-Sandin S, Novalbos J, Rosado A, Cano-Abad MF, Arias E, et al. (2005) Albumin prevents mitochondrial depolarization and apoptosis elicited by endoplasmic reticulum calcium depletion of neuroblastoma cells. Eur J Pharmacol 520: 1-11.
26. Tabernero A, Granda B, Medina A, Sanchez-Abarca LI, Lavado E, et al. (2002) Albumin promotes neuronal survival by increasing the synthesis and release of glutamate. J Neurochem 81: 881-891.
27. Tabernero A, Medina A, Sanchez-Abarca LI, Lavado E, Medina JM, (1999) The effect of albumin on astrocyte energy metabolism is not brought about through the control of cytosolic Ca2+ concentrations but by free-fatty acid sequestration. Glia 25: 1-9.
28. Wayner DD, Burton GW, Ingold KU, Locke S, (1985) Quantitative measurement of the total, peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. The important contribution made by plasma proteins. FEBS Lett 187: 33-37.
29. Belayev L, Saul I, Busto R, Danielyan K, Vigdorchik A, et al. (2005) Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat. Stroke 36: 326-331.
30. Liu Y, Belayev L, Zhao W, Busto R, Belayev A, et al. (2001) Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. Eur J Pharmacol 428: 193-201.
31. Ginsberg MD, Zhao W, Belayev L, Alonso OF, Liu Y, et al. (2001) Diminution of metabolism/blood flow uncoupling following traumatic brain injury in rats in response to high-dose human albumin treatment. J Neurosurg 94: 499-509.
32. Bowenkamp KE, David D, Lapchak PL, Henry MA, Granholm AC, et al. (1996) 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp Brain Res 111: 1-7.
33. Sauer H, Oertel WH, (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59: 401-415.
34. Remmers M, Schmidt-Kastner R, Belayev L, Lin B, Busto R, et al. (1999) Protein extravasation and cellular uptake after high-dose human-albumin treatment of transient focal cerebral ischemia in rats. Brain Res 827: 237-242.
35. Juurlink BH, Devon RM, (1990) Macromolecular translocation - a possible function of astrocytes. Brain Res 533: 73-77.
36. Schnitzer JE, Sung A, Horvat R, Bravo J, (1992) Preferential interaction of albumin-binding proteins, gp30 and gp18, with conformationally modified albumins. Presence in many cells and tissues with a possible role in catabolism. J Biol Chem 267: 24544-24553.
37. Xue YQ, Zhao LR, Guo WP, Duan WM, (2007) Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease. Neuroscience 146: 1245-1258.
38. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, et al. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65: 135-172.
39. Eminel S, Klettner A, Roemer L, Herdegen T, Waetzig V, (2004) JNK2 translocates to the mitochondria and mediates cytochrome c release in PC12 cells in response to 6-hydroxydopamine. J Biol Chem 279: 55385-55392.
40. Saito Y, Nishio K, Ogawa Y, Kinumi T, Yoshida Y, et al. (2007) Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and-independent action. Free Radic Biol Med 42: 675-685.
41. Rodriguez-Blanco J, Martin V, Herrera F, Garcia-Santos G, Antolin I, et al. (2008) Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine. J Neurochem 107: 127-140.
42. Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, et al. (2002) Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection. Circ Res 90: 390-397.
43. Chu CT, Levinthal DJ, Kulich SM, Chalovich EM, DeFranco DB, (2004) Oxidative neuronal injury. The dark side of ERK1/2. Eur J Biochem 271: 2060-2066.
44. Zhuang S, Schnellmann RG, (2006) A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 319: 991-997.
45. Dagda RK, Zhu J, Kulich SM, Chu CT, (2008) Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. Autophagy 4: 770-782.
46. de Bernardo S, Canals S, Casarejos MJ, Solano RM, Menendez J, et al. (2004) Role of extracellular signal-regulated protein kinase in neuronal cell death induced by glutathione depletion in neuron/glia mesencephalic cultures. J Neurochem 91: 667-682.
47. Luo Y, DeFranco DB, (2006) Opposing roles for ERK1/2 in neuronal oxidative toxicity: distinct mechanisms of ERK1/2 action at early versus late phases of oxidative stress. J Biol Chem 281: 16436-16442.
48. Canals S, Casarejos MJ, de Bernardo S, Solano RM, Mena MA, (2003) Selective and persistent activation of extracellular signal-regulated protein kinase by nitric oxide in glial cells induces neuronal degeneration in glutathione-depleted midbrain cultures. Mol Cell Neurosci 24: 1012-1026.
49. Kulich SM, Chu CT, (2001) Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J Neurochem 77: 1058-1066.
50. Jeohn GH, Cooper CL, Wilson B, Chang RC, Jang KJ, et al. (2002) p38 MAP kinase is involved in lipopolysaccharide-induced dopaminergic neuronal cell death in rat mesencephalic neuron-glia cultures. Ann N Y Acad Sci 962: 332-346.
51. Choi WS, Eom DS, Han BS, Kim WK, Han BH, et al. (2004) Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8- and-9-mediated apoptotic pathways in dopaminergic neurons. J Biol Chem 279: 20451-20460.
52. Saporito MS, Brown EM, Miller MS, Carswell S, (1999) CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. J Pharmacol Exp Ther 288: 421-427.
53. Newhouse K, Hsuan SL, Chang SH, Cai B, Wang Y, et al. (2004) Rotenone-induced apoptosis is mediated by p38 and JNK MAP kinases in human dopaminergic SH-SY5Y cells. Toxicol Sci 79: 137-146.
54. Klintworth H, Newhouse K, Li T, Choi WS, Faigle R, et al. (2007) Activation of c-Jun N-terminal protein kinase is a common mechanism underlying paraquat- and rotenone-induced dopaminergic cell apoptosis. Toxicol Sci 97: 149-162.
55. Pan J, Zhao YX, Wang ZQ, Jin L, Sun ZK, et al. (2007) Expression of FasL and its interaction with Fas are mediated by c-Jun N-terminal kinase (JNK) pathway in 6-OHDA-induced rat model of Parkinson disease. Neurosci Lett 428: 82-87.
56. Wu SS, Frucht SJ, (2005) Treatment of Parkinson's disease: what's on the horizon? CNS Drugs 19: 723-743.
57. Xia XG, Harding T, Weller M, Bieneman A, Uney JB, et al. (2001) Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98: 10433-10438.
58. Ganguly A, Oo TF, Rzhetskaya M, Pratt R, Yarygina O, et al. (2004) CEP11004, a novel inhibitor of the mixed lineage kinases, suppresses apoptotic death in dopamine neurons of the substantia nigra induced by 6-hydroxydopamine. J Neurochem 88: 469-480.
59. Hanson RW, Ballard FJ, (1968) Citrate, pyruvate, and lactate contaminants of commercial serum albumin. J Lipid Res 9: 667-668.
60. Jones RG, Liu Y, Halls C, Thorpe SJ, Longstaff C, et al. (2011) Release of proteolytic activity following reduction in therapeutic human serum albumin containing products: detection with a new neoepitope endopeptidase immunoassay. J Pharm Biomed Anal 54: 74-80.
61. Ungerstedt U, Arbuthnott GW, (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24: 485-493.
62. Duan WM, Widner H, Brundin P, (1995) Temporal pattern of host responses against intrastriatal grafts of syngeneic, allogeneic or xenogeneic embryonic neuronal tissue in rats. Exp Brain Res 104: 227-242.
63. Duan WM, Widner H, Cameron RM, Brundin P, (1998) Quinolinic acid-induced inflammation in the striatum does not impair the survival of neural allografts in the rat. Eur J Neurosci 10: 2595-2606.
64. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J, (2001) Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 29: 629-643.
65. Huang S, Shu L, Dilling MB, Easton J, Harwood FC, et al. (2003) Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell 11: 1491-1501.
66. Liu L, Li F, Cardelli JA, Martin KA, Blenis J, et al. (2006) Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 25: 7029-7040.